Actuate Therapeutics ACTU 深 沪
等待开盘 10-08 09:30:00 美东时间
7.04
+0.020
+0.28%
华盛通- 最 高7.10
- 今 开7.08
- 成交量 2.76万股
- 最 低 6.87
- 昨 收 7.02
- 总市值 1.61亿
- 52周最高 11.99
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 5.47
- 委 比 39.48%
- 总股本 2292.19万
- 历史最高 11.99
- 量 比 0.61
- 振 幅 3.28%
- 历史最低 5.47
- 每 手 1
- 风险率 1.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Actuate Therapeutics Advances Elraglusib As Potential Backbone Therapy For Pancreatic Cancer With Phase 2 Data Supporting Upcoming FDA And EMA Submissions
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through
09-22 20:47
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Actuate Therapeutics announced positive findings for elraglusib, a GSK-3β inhibitor, showing improved survival in metastatic pancreatic cancer when combined with gemcitabine/nab-paclitaxel (GnP). The Phase 2 trial demonstrated a statistically significant increase in median overall survival, with a 37% reduction in death risk and doubled 12-month survival rate. The company secured $17.25 million to advance regulatory submissions and further studie...
09-22 12:45
Actuate Therapeutics Prices $15M Public Offering Of 2,142,858 Shares At A Price Of $7.00/Share
Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the
09-10 20:39
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 7.7% to $2...
09-10 05:06
Actuate Therapeutics shares are trading lower after the company announced an underwritten public offering.
Actuate Therapeutics shares are trading lower after the company announced an un...
09-10 04:24
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
Actuate Therapeutics, Inc. announced its intent to conduct an underwritten public offering of its common stock, with an option for underwriters to purchase up to an additional 15% of shares. Proceeds will be used for working capital and general corporate purposes. Lucid Capital Markets is sole book-running manager. The offering is subject to market conditions, and additional details are available in the SEC filings.
09-09 20:07
Actuate Therapeutics files $250M mixed securities shelf
Actuate Therapeutics (NASDAQ:ACTU) filed a prospectus for the offer and sale of $250M mixed securities shelf. This prospectus is not an offer to sell these securities. Filing. More on Actuate Therapeu...
09-03 04:35
B. Riley Securities Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $20
B. Riley Securities analyst Mayank Mamtani initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and announces Price Target of $20.
08-26 18:22
